Q-omics provides the consensus-scored FOXJ1 profile across patient tissues and cancer cell-line models. FOXJ1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FOXJ1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, FOXJ1 RNA expression shows 14,996 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KICH, and TGCT as cancer lineages where FOXJ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXJ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXJ1 survival associations across molecular data types. FOXJ1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXJ1 RNA expression–survival associations across cancer types. High FOXJ1 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in HNSC, BRCA and LUSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FOXJ1 RNA expression.
This table summarizes FOXJ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FOXJ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXJ1 shows lower tumor expression in KICH, THCA, KIRC and LUSC and higher tumor expression in STAD and BRCA. The KICH box plot shows higher FOXJ1 RNA expression in normal versus tumor tissue (log2 FC = −3.621, t-test p < 0.001).
This table shows molecular features associated with FOXJ1 in patient tissues and cancer cell lines. In patient samples, FOXJ1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXJ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and OVARY.
